| Xiangyu Meng,Xiaoping Liu,Chunrui Li,Cheng Fang,Li He. IGIACP1 predicts the prognosis in multiple myeloma patients. Oncol Transl Med, 2017, 3: 217-220. |
| IGIACP1 predicts the prognosis in multiple myeloma patients |
| Received:August 07, 2017 Revised:September 08, 2017 |
| View Full Text View/Add Comment Download reader |
| KeyWord:multiple myeloma; prognosis; ACP1; low-molecular-weight protein tyrosine phosphatase (LMWPTP) |
| Author Name | Affiliation | E-mail | | Xiangyu Meng | Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | mengxy_whu@163.com | | Xiaoping Liu | Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | | | Chunrui Li | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | | | Cheng Fang | Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | | | Li He | Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | lihe_whu@163.com |
|
| Hits: 6413 |
| Download times: 7500 |
| Abstract: |
| Objective The aim of this study was to investigate the prognostic relevance of acid phosphatase 1
(ACP1) expression in myeloma patients by using Gene Expression Omnibus (GEO) datasets.
Methods A comprehensive search was performed in the GEO database in order to find appropriate
datasets. The expression level of ACP1 was extracted from the dataset involving both newly diagnosed
and relapsed myeloma patients, and a comparison was made. Clinical follow-up data and ACP1 expression
were extracted, and survival analysis of overall survival was performed to compare the high- (top quartile)
and low-expression (bottom quartile) groups. Analyses using Kaplan-Meier estimation, log-rank test, and
restricted mean survival time (RMST) comparison were performed.
Results The GSE 6477 dataset was used to make a comparison of the ACP1 expression levels among
patients with newly diagnosed and relapsed myeloma. The ACP1 expression level was significantly higher
in the relapsed group than in the newly diagnosed group [mean difference = -262.9, 95% confidence
interval (CI) = (-420.2, -105.5), P = 0.002]. The GSE 2658 dataset was used for investigating the prognostic
relevance of ACP1 expression in myeloma. The ACP1 high-expression group had a significantly worse
prognosis [low vs high: hazard ratio = 0.54, 95% CI = (0.31, 0.95); χ2 = 5.02, log rank P = 0.0314]. The
median survival was 55.9 months in the high-expression group and was not reached in the low-expression
group. The restricted mean time loss (95% CI) was 11.03 (12.97, 23.11) and 18.04 (12.97, 23.11) for the
low- and high-expression groups, respectively. The ratio of RMST (95% CI) between the two groups (high
vs low) was 0.87 (0.77, 0.99; P = 0.03).
Conclusion Our study, for the first time, showed that ACP1 predicts the prognosis in multiple myeloma
patients. Further studies are needed to determine the potential mechanism by which ACP1 is associated
with clinical outcomes and should focus on the differential roles of low-molecular-weight protein tyrosine
phosphatase (LMWPTP) isoforms. |
| Close |
|
|
|